专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110281790A1 INSULIN WITH A STABLE BASAL RELEASE PROFILE 有权
标题翻译：胰岛素具有稳定的基本释放特征
公开(公告)号：US20110281790A1
公开(公告)日：2011-11-17
申请号：US12778719
申请日：2010-05-12
申请人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
发明人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
IPC分类号： A61K38/28 , B65D69/00 , A61P3/10
CPC分类号： A61K9/0021 , A61K9/0024 , A61K9/19 , A61K38/28 , A61K47/02 , A61K47/183 , A61K47/26
摘要： A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.
摘要翻译：已经开发了用于皮下，皮内或肌肉内施用的由胰岛素，优选甘精胰岛素，可注射锌和可注射铁化合物作为沉淀和/或稳定剂的基础胰岛素制剂。该制剂被设计为在注射后形成胰岛素沉淀，在12至24小时的时间段内产生缓慢释放的“基础胰岛素”。

2. 发明授权

US08637458B2 Insulin with a stable basal release profile 有权
标题翻译：胰岛素具有稳定的基础释放特征
公开(公告)号：US08637458B2
公开(公告)日：2014-01-28
申请号：US12778719
申请日：2010-05-12
申请人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
发明人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
IPC分类号： A61K38/28 , C07K14/62
CPC分类号： A61K9/0021 , A61K9/0024 , A61K9/19 , A61K38/28 , A61K47/02 , A61K47/183 , A61K47/26
摘要： A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.
摘要翻译：已经开发了用于皮下，皮内或肌肉内施用的由胰岛素，优选甘精胰岛素，可注射锌和可注射铁化合物作为沉淀和/或稳定剂的基础胰岛素制剂。该制剂被设计成在注射后形成胰岛素沉淀，在12至24小时的时间段内产生缓慢释放的“基础胰岛素”。

3. 发明申请

US20100069292A1 INSULIN WITH A BASAL RELEASE PROFILE 审中-公开
标题翻译：胰岛素具有基本释放特征
公开(公告)号：US20100069292A1
公开(公告)日：2010-03-18
申请号：US12552855
申请日：2009-09-02
申请人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
发明人： Roderike Pohl , Nandini Kashyap , Robert Hauser , Koray Ozhan , Solomon S. Steiner
IPC分类号： A61K38/28
CPC分类号： A61K47/02 , A61K9/0019 , A61K38/28 , A61K47/183
摘要： A clear basal insulin formulation composed of insulin (preferably human recombinant insulin), buffering agents, precipitating agents, and/or stabilizing agents for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours, which can be varied by compositional changes to tailor the release profile to the needs of the individual diabetic patient
摘要翻译：由胰岛素（优选人重组胰岛素），缓冲剂，沉淀剂和/或用于皮下，皮内或肌内给药的稳定剂组成的清楚的基础胰岛素制剂。该制剂被设计成在注射后形成胰岛素沉淀，在12至24小时的时间段内产生缓慢释放的“基础胰岛素”，这可以通过组合变化而变化，以根据个体糖尿病患者的需要调整释放曲线

4. 发明申请

US20090175840A1 INSULIN FORMULATIONS FOR INSULIN RELEASE AS A FUNCTION OF TISSUE GLUCOSE LEVELS 审中-公开
标题翻译：胰岛素释放作为组织葡萄糖水平的功能的胰岛素制剂
公开(公告)号：US20090175840A1
公开(公告)日：2009-07-09
申请号：US12348839
申请日：2009-01-05
申请人： Nandini Kashyap , Solomon S. Steiner , Roderike Pohl
发明人： Nandini Kashyap , Solomon S. Steiner , Roderike Pohl
IPC分类号： A61K38/44 , A61K38/28 , A61K38/43 , A61P3/10
CPC分类号： A61K9/0019 , A61K38/28 , A61K47/46
摘要： Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range. The formulation is often referred to as a “smart” formulation since it modifies its release rate of insulin according to the patient's needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile.
摘要翻译：本文描述了能够改变基于患者组织葡萄糖水平释放的胰岛素量的可注射胰岛素制剂，制备和使用这些制剂的方法。制剂可以通过皮下，皮内或肌肉内施用来施用。在一个优选的实施方案中，通过皮下注射施用制剂。制剂含有胰岛素，氧化剂或酶，还原剂或酶，稀释剂和任选的一种或多种增稠剂。如果制剂中存在增稠剂，则增稠剂在给药后增加制剂的粘度。优选地，制剂含有胰岛素，稀释剂，葡萄糖氧化酶和过氧化物酶。在给予患者之后，胰岛素作为患者组织葡萄糖水平的函数从制剂中释放，其又将患者的血糖水平维持在最佳范围内。该制剂通常被称为“智能”制剂，因为其在特定时间根据患者的需要改变其胰岛素的释放速率。在优选的实施方案中，所述制剂被设计为在患者中注射后具有基础释放曲线随时间将胰岛素释放到全身循环中。在另一个实施方案中，所述制剂被设计成在患者注射后，例如常规人胰岛素释放曲线或餐时释放曲线，随着时间推移胰岛素进入体循环随着非基础释放曲线。

5. 发明授权

US09610329B2 Stabilized glucagon solutions 有权
公开(公告)号：US09610329B2
公开(公告)日：2017-04-04
申请号：US12891240
申请日：2010-09-27
申请人： Solomon S. Steiner , Robert Hauser , Ming Li , Robert Feldstein , Roderike Pohl
发明人： Solomon S. Steiner , Robert Hauser , Ming Li , Robert Feldstein , Roderike Pohl
IPC分类号： A61K38/26 , A61K9/107 , A61K47/24 , A61K47/26 , A61K9/00 , A61K9/19
CPC分类号： A61K38/26 , A61K9/0019 , A61K9/1075 , A61K9/19 , A61K47/26
摘要： A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C.

6. 发明授权

US08950397B2 Unit dose cartridge and dry powder inhaler 有权
标题翻译：单位剂量筒和干粉吸入器
公开(公告)号：US08950397B2
公开(公告)日：2015-02-10
申请号：US13490292
申请日：2012-06-06
申请人： Solomon S. Steiner , Trent A. Poole , Per B. Fog , Roderike Pohl , Michael Crick , Robert Feldstein
发明人： Solomon S. Steiner , Trent A. Poole , Per B. Fog , Roderike Pohl , Michael Crick , Robert Feldstein
IPC分类号： A61M11/00 , A61M15/00 , A61M16/04
CPC分类号： A61M15/0015 , A61M15/002 , A61M15/0023 , A61M15/0025 , A61M15/0028 , A61M15/0086 , A61M16/0495 , A61M16/0825 , A61M2202/064 , A61M2205/43
摘要： A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.
摘要翻译：描述了具有改善的空气动力学特性以用于稀释，分散和计量药物颗粒以提高肺部药物递送给患者的效率的干粉吸入器。吸入器通常包括具有进气口的壳体，空气流量控制/止回阀，混合部分和吹嘴。装有单剂量药物的药筒可以安装在混合部分中。

7. 发明申请

US20120240929A1 UNIT DOSE CARTRIDGE AND DRY POWDER INHALER 有权
标题翻译：单位剂量桶和干粉吸入器
公开(公告)号：US20120240929A1
公开(公告)日：2012-09-27
申请号：US13490292
申请日：2012-06-06
申请人： Solomon S. Steiner , Trent A. Poole , Per B. Fog , Roderike Pohl , Michael Crick , Robert Feldstein
发明人： Solomon S. Steiner , Trent A. Poole , Per B. Fog , Roderike Pohl , Michael Crick , Robert Feldstein
IPC分类号： A61M15/00
CPC分类号： A61M15/0015 , A61M15/002 , A61M15/0023 , A61M15/0025 , A61M15/0028 , A61M15/0086 , A61M16/0495 , A61M16/0825 , A61M2202/064 , A61M2205/43
摘要： A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.
摘要翻译：描述了具有改善的空气动力学特性以用于稀释，分散和计量药物颗粒以提高肺部药物递送给患者的效率的干粉吸入器。吸入器通常包括具有进气口的壳体，空气流量控制/止回阀，混合部分和吹嘴。装有单剂量药物的药筒可以安装在混合部分中。

8. 发明申请

US20100227795A1 INSULIN FORMULATIONS FOR RAPID UPTAKE 有权
标题翻译：胰岛素制剂用于快速摄取
公开(公告)号：US20100227795A1
公开(公告)日：2010-09-09
申请号：US12397219
申请日：2009-03-03
申请人： Solomon S. Steiner , Roderike Pohl , Ming Li , Robert Hauser
发明人： Solomon S. Steiner , Roderike Pohl , Ming Li , Robert Hauser
IPC分类号： A61K38/28 , A61P3/10
CPC分类号： A61K9/0019 , A61K38/00 , A61K38/28 , A61K47/12 , A61K47/183 , C07K14/62
摘要： Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration. In another embodiment, the insulin is stored as a frozen mixture, ready for use upon thawing.
摘要翻译：本文描述了具有改善的稳定性和快速起效的可注射的胰岛素制剂。制剂可用于皮下，皮内或肌内给药。在优选的实施方案中，通过皮下注射施用制剂。制剂含有与螯合剂和溶解剂以及任选的其它赋形剂组合的胰岛素。在优选的实施方案中，制剂含有人胰岛素，锌螯合剂如EDTA和溶解剂如柠檬酸或柠檬酸钠。当通过皮下注射给药时，这些制剂被快速地吸收到血流中。在优选的实施方案中，胰岛素以多用途无菌小瓶中的透明液体中性pH提供。在替代实施方案中，胰岛素以无菌小瓶中的粉末形式提供。将其与包含药学上可接受的载体如水，锌螯合剂如EDTA的稀释剂和不久之前或给药时的溶解剂如柠檬酸混合。在另一个实施方案中，将胰岛素作为冷冻混合物储存，准备在解冻时使用。

9. 发明申请

US20090137455A1 RAPID ACTING AND LONG ACTING INSULIN COMBINATION FORMULATIONS 有权
标题翻译：快速行动和长期行动胰岛素组合制剂
公开(公告)号：US20090137455A1
公开(公告)日：2009-05-28
申请号：US12324717
申请日：2008-11-26
申请人： Solomon S. Steiner , Roderike Pohl
发明人： Solomon S. Steiner , Roderike Pohl
IPC分类号： A61K38/28 , A61P3/00
CPC分类号： A61K31/185 , A61K9/0014 , A61K31/19 , A61K31/385 , A61K38/28 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/183 , A61K47/26 , A61K2300/00
摘要： An injectable formulation containing a combination of a rapid acting insulin and a long acting insulin has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting insulin, e.g. insulin glargine, remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for up to 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. Alternatively, through adjustment of the ratio of rapid acting insulin to long acting insulin, the long acting insulin may be shortened to a 12 hour formulation. This rapid and long acting blend is re-administered to the patient at dinner time, providing a safe and effective basal insulin level until morning. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.
摘要翻译：已经开发了含有快速作用的胰岛素和长效胰岛素的组合的可注射制剂，其中调节快速作用的胰岛素的pH，使得长效胰岛素例如。甘精胰岛素，当它们混合在一起时，保持可溶。在优选的实施方案中，该可注射的基础推注胰岛素在早餐之前施用，提供足够的推注胰岛素水平以覆盖膳食，在餐后不产生低血糖并提供足够的基础胰岛素达24小时。午餐和晚餐可以通过快速作用或快速作用或非常快速作用的胰岛素的两次快速注射来覆盖。或者，通过调整速效胰岛素与长效胰岛素的比例，长效胰岛素可缩短至12小时制剂。这种快速和长效的混合物在晚餐时间重新施用于患者，提供安全有效的基础胰岛素水平直到早晨。因此，使用强化胰岛素治疗的患者每天只能注射三次，而不是四次。

10. 发明授权

US06991779B2 Compositions for treatment or prevention of bioterrorism 有权
标题翻译：用于治疗或预防生物恐怖主义的组成部分
公开(公告)号：US06991779B2
公开(公告)日：2006-01-31
申请号：US10347932
申请日：2003-01-17
申请人： Solomon S. Steiner , Cohava Gelber , Robert S. Feldstein , Roderike Pohl
发明人： Solomon S. Steiner , Cohava Gelber , Robert S. Feldstein , Roderike Pohl
IPC分类号： A61K9/12 , A61K9/72
CPC分类号： A61K9/0075 , A61K9/1617 , A61K9/1641 , A61K31/46 , A61K31/495 , A61K39/00 , A61K39/07 , A61K2039/505 , A61K2039/55555 , C07K16/12
摘要： Compositions containing biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres (TECHNOSPHEREs™) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals against agents of biological warfare. The biologically active molecules include atropine, antibodies, antigens, and antibiotics. The compositions can be placed in an inhalation device for self-administration. Pulmonary delivery of TECHNOSPHERE™ encapsulated atropine, antibodies, vaccines, and antibiotics provides an accelerated onset of immunity to the targeted disease. Furthermore, the TECHNOSPHERE™ encapsulated atropine, antibodies, vaccines, and antibiotics are stable formulations, suitable for stockpiling, rapid dissemination and mass treatment.
摘要翻译：包含自组装，二酮哌嗪微球体（TECHNOSPHERE TM）中的生物活性分子的组合物以及制备和施用此类组合物的方法在本文中描述。组合物可用于免疫个体对生物战的药剂。生物活性分子包括阿托品，抗体，抗原和抗生素。组合物可以放置在用于自我给药的吸入装置中。包含阿托品，抗体，疫苗和抗生素的TECHNOSPHERE TM的肺转运提供了对目标疾病免疫的加速发作。此外，TECHNOSPHERE（TM）包裹阿托品，抗体，疫苗和抗生素是稳定的配方，适合储存，快速传播和大量治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式